so proud to present our international collaboration with Danish colleagues at #EHA2026, brilliant Dr. Oğuzhan Koca being the leading author, introducing a new prognostic score predicting both progression-free (#PFS) and overall (#OS) survivals in pts with primary mediastinal B cell lymphoma (#PMBCL) 🤓🥰😎🙌
@EHA_Hematology
⚡ The Fastest BCMA CAR-T Yet?
Durca-cel (PHE885) Delivers Deep Responses in RRMM — But Are We Ready for the Next CAR-T Revolution? 🧵
Phase 1 data in Science Translational Medicine 👇
1/ Why does this matter? 🤔⚡
Current autologous CAR-T manufacturing can be prolonged, creating major challenges for patients with rapidly progressive RRMM:
➡️ need for bridging therapy
➡️ risk of clinical deterioration before infusion
➡️ possible T-cell exhaustion during manufacturing
#mmsm #myeloma #MedEd #medtwitter #USMIRC @USMIRCNEWS@US_HMC@oncodaily@MedwatchKate@Larvol
🩺 Sex during neutropenia — what should we tell patients?
JCO Oncology Practice:
• ❤️🩹 Sexual health remains important for quality of life during cancer treatment
• 📉 Evidence for strict sexual restrictions in neutropenia is limited
• 🤝 Stable monogamous partners: condoms not routinely required if partner healthy
• ⚠️ Avoid anal sex/fecal exposure, new partners, or sex during severe mucositis
• 🚿 Gentle hygiene is sufficient; over-washing may harm mucosa
• 💊 Condoms may be used briefly after chemotherapy to protect partners from drug exposure
💡 Takeaway: counseling should be individualized and evidence-informed, not based on outdated blanket restrictions.
📄 https://t.co/yc52ULwLpg
#HemOnc #Neutropenia #CancerCare #QualityOfLife @IMG_Oncologists@oncodaily@HemOncFellows
just finished proof editing of our paper to be published in the American Journal of Hematology discussing a recently introduced survival predictor in essential thrombocythemia, the AAA+ model 🤓😎🔥
#ET#MPNsm@WileyGlobal@AjHematology
Just in: Good news for the myeloma field.
FDA approves teclistamab plus daratumumab (Tec-Dara) combination for myeloma for patients who have had at least one prior line of therapy.
Note: Always use Tec-Dara with monthly IVIG. It’s not optional.
That was fast! And this is unprecedented curve is why.
When someone speaks badly about someone else, I’ve learned to ask a question
Is there a conflict of interest here?
Because for some people, discharging others is far too easy
And if becoming a good academic requires giving up being a decent human being, there is a serious problem
Establishment Archaeologists are going to be BIG mad over my upcoming video
See all this dirt, stone and rubble?
Excavating Gobekli Tepe is a literal rubble removal project 💯
Archaeologists have SO many things wrong about this site, I think their heads are gonna explode 😂
Years ago, when I reached out to a kind mentor @ManniMD1 for collaboration, he asked why I wanted to publish. I said “Because people ask about it (for jobs, fellowships etc)” Honest, but nonsense. Believe in publishing only when it makes sense to me, then I will refer to this😅🙏
All my 2026 current myeloma algorithms in one thread. From smoldering to newly diagnosed to relapsed. Bookmark!
#ASH25#ASH25VR
1/ Smoldering Myeloma
Main message: I recommend Daratumumab X 3 years for high risk smoldering myeloma.
OK took a while by here it is.
My #ASH25 algorithm for myeloma, second relapse. Discussed with @myelomaMD
It’s hard to pick the best between the options because there are many variables. But it will help with the approach.
NO ONE should pay to submit an abstract to a scientific conference.
Your abstracts should not be a revenue stream for medical societies.
Please, stop this NOW🙏
How would I ever be able to take care of my patients with myeloma without the 50 guidelines on infectious ppx after CART and BiTEs?
I’ll save everyone time
IVIG monthly
Acyclovir 400 mg BID
Bactrim M,W,F
For BITEs hold if neutropenic